126674-77-9

Basic information

• Product Name: 2-AMINO-4,6-DIFLUOROBENZOIC ACID
• Synonyms: 2-AMINO-4,6-DIFLUOROBENZOIC ACID;BUTTPARK 49\07-42;2-Amino-4,6-difluorobenzoic acid ,97%;2-Carboxy-3,5-difluoroaniline, 4,6-Difluoroanthranilic acid;2-AMino-4,6-difluorobenzoic acid 97%;Benzoic acid, 2-aMino-4,6-difluoro-;2-AMino-4,6-difluorobenzoic acid, 6-difluorobenzoic acid
• CAS NO: 126674-77-9
• Molecular Formula: C₇H₅F₂NO₂
• Molecular Weight: 173.12
• Mol File: 126674-77-9.mol

Chemical Properties

• Boiling Point: 305.752 °C at 760 mmHg
• Flash Point: 138.714 °C
• Appearance: /
• Density: 1.536
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.578
• PKA: 3.95±0.10(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 2-AMINO-4,6-DIFLUOROBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-4,6-DIFLUOROBENZOIC ACID(126674-77-9)
• EPA Substance Registry System: 2-AMINO-4,6-DIFLUOROBENZOIC ACID(126674-77-9)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 126674-77-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-4,6-Difluorobenzoic Acid is used as an intermediate compound for the synthesis of various pharmaceuticals. Its unique structure, including the presence of fluorine atoms, can contribute to the development of new drugs with improved properties, such as increased potency, selectivity, or bioavailability.
Used in Chemical Research:
2-Amino-4,6-Difluorobenzoic Acid serves as a valuable research tool in the field of organic chemistry, particularly in the study of fluorine-containing compounds. Its reactivity and properties can be explored for the development of new synthetic methods, reactions, or applications in various chemical processes.
Used in Material Science:
2-Amino-4,6-Difluorobenzoic Acid may be utilized in the development of new materials with specific properties, such as improved thermal stability, chemical resistance, or electronic properties. Its incorporation into polymers or other materials can lead to the creation of advanced materials for various applications, including electronics, coatings, or adhesives.

InChI:InChI=1/C7H5F2NO2/c8-3-1-4(9)6(7(11)12)5(10)2-3/h1-2H,10H2,(H,11,12)

Upstream product

• 126674-93-9 4,6-difluoro-1H-indole-2,3-dione 
• 190011-84-8 2-amino-4,6-difluorobenzonitrile 
• 372-39-4 3,5-difluoroaniline 
• 940054-61-5 N-(3,5-difluorophenyl)-2-hydroxyiminoacetamide 

Downstream Products

• 379228-58-7 5,7-difluoroquinazolin-4(3H)-one 
• 59-31-4 2-quinolone 
• 940054-62-6 2-amino-4,6-difluorobenzoic acid cyanomethyl ester 
• 893428-66-5 2-amino-4,6-difluoro-benzamide 
• 379228-57-6 methyl 2-amino-4,6-difluorobenzoate 
• 1352144-72-9 C₁₁H₈F₂N₂O 
• 1352144-73-0 C₁₁H₁₀F₂N₂*ClH 
• 1352144-74-1 C₂₀H₁₆F₄N₂O 
• 1352144-52-5 4-[4-(1,1-difluoroethyl)phenyl]-7,9-difluoro-6H-pyrrolo[1,2-a][1,4]benzodiazepine 
• 1352144-71-8 C₁₁H₇F₂NO₂ 
• 1378963-19-9 1-[4-(7,9-difluoro-5,6-dihydro-4H-pyrrolo[1,2-a][1,4]benzodiazepin-4-yl)phenyl]ethanone hydrochloride 
• 1379150-67-0 1-[4-(7,9-difluoro-6H-pyrrolo[1,2-a][1,4]benzodiazepin-4-yl)phenyl]ethanone 
• 1246250-74-7 5,7-difluoro-2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-3H-quinazolin-4-one 
• 1253731-71-3 2-(4-benzyloxy-3,5-dimethylphenyl)-5,7-difluoro-3H-quinazolin-4-one 

Relevant articles and documents

TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY

The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.

ANTIFUNGAL 5,6-DIHYDRO-4H-PYRROLO[1,2-A][1,4]-BENZODIAZEPINES AND 6H-PYRROLO[1,2-A][1,4]BENZODIAZEPINES SUBSTITUTED WITH PHENYL DERIVATIVES

The present invention is concerned with novel antifungal 5,6-dihydro-4H-pyrrolo-[1,2-a][1,4]benzodiazepines and 6H-pyrrolo[1,2-a][1,4]benzodiazepines of Formula (I) wherein R1, R2, R3, R4, R5 and Rsu

Process research and development for the kilogram manufacture of the SRC kinase inhibitor AZD0530

Process research and development of a synthetic route towards a novel SRC kinase inhibitor is described. The Medicinal Chemistry route was very long and suffered from extensive use of chlorinated solvents and chromatography. A number of steps in the Medic

Pyrrolidine(thi)ones Substituted by Heterocyclic Substituents in The 3-Position

Pyrrolidine(thi)one compounds substituted by heterocyclic substituents in the 3-position, their preparation and use in pharmaceutical compositions, in particular as immunomodulators for treatment and/or inhibition of inflammatory and autoimmune diseases and haematological-oncological diseases.

CHEMICAL PROCESS

The present invention relates to chemical processes useful in the manufacture of the compound 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]- 5-tetrahydropyran-4-yloxyquinazoline (the active entity within AZD0530), to intermed

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy] -5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor

Src family kinases (SFKs) are nonreceptor tyrosine kinases that are reported to be critical for cancer progression. We report here a novel subseries of C-5-substituted anilinoquinazolines that display high affinity and specificity for the tyrosine kinase domain of the c-Src and Abl enzymes. These compounds exhibit high selectivity for SFKs over a panel of recombinant protein kinases, excellent pharmacokinetics, and in vivo activity following oral dosing. N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine (AZD0530) inhibits c-Src and Abl enzymes at low nanomolar concentrations and is highly selective over a range of kinases. AZD0530 displays excellent pharmacokinetic parameters in animal preclinically and in man (t1/2 = 40 h). AZD0530 is a potent inhibitor of tumor growth in a c-Src-transfected 3T3-fibroblast xenograft model in vivo and led to a significant increase in survival in a highly aggressive, orthotopic model of human pancreatic cancer when dosed orally once daily. AZD0530 is currently undergoing clinical evaluation in man.